)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Hugel
Hugel (145020) investor relations material
Hugel Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 2026 sales were KRW 97.5bn, down 8% YoY; operating profit fell 62% to KRW 18.1bn and net income fell 88% to KRW 4.7bn.
9M revenue rose to KRW 352.1bn from KRW 306.0bn, while operating income declined to KRW 121.7bn from KRW 143.0bn and net income to KRW 90.1bn from KRW 107.1bn.
Financial highlights
Q3 gross profit was KRW 73.0bn, down 11% YoY; SG&A increased 60% to KRW 54.9bn. Gross margin was 74.9% and operating margin 18.6%.
9M gross profit was KRW 268.8bn versus KRW 237.3bn; SG&A rose to KRW 147.1bn from KRW 94.3bn, contributing to lower operating income.
9M operating cash flow was KRW 120.5bn versus KRW 85.3bn; cash and cash equivalents were KRW 234.9bn at Sep. 30, 2026, versus KRW 209.7bn at year-end 2025.
Segment performance
Q3 toxin revenue was KRW 47.2bn, down 21% YoY; filler and skinbooster revenue was KRW 30.9bn, up 2%. Cosmetics and others revenue rose 25% to KRW 19.4bn.
Q3 Korea sales were KRW 27.4bn, up 54% YoY; international toxin and filler sales were KRW 50.8bn, down 30%. APAC sales were KRW 33.1bn, down 8%; Europe and others rose 18% to KRW 17.8bn.
North and South American toxin and filler revenue was negative in Q3 due to a change in U.S. operating strategy.
9M toxin revenue was KRW 193.2bn versus KRW 162.8bn; filler and skinbooster revenue was KRW 96.7bn versus KRW 96.1bn, and cosmetics revenue was KRW 54.8bn versus KRW 40.9bn.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Hugel
- US expansion and portfolio growth underpin the KRW 900bn 2028 revenue target.145020
Investor Day 2026 presentation - H1 2026 revenue reached KRW 254.5bn, led by toxin sales and strong international growth.145020Q2 2026
- Operating profit surged 54.5% year-over-year, driven by strong toxin and global sales growth.145020Q3 2024
- Double-digit sales and profit growth in 4Q24, led by Toxin, Filler, and Cosmetics segments.145020Q4 2024
- H1 2024 revenue hit ₩169.7B, net income ₩59.7B, driven by global expansion and strong cash position.145020Q2 2024
- Q1 2026 delivered strong growth, led by botulinum toxin and international sales, with robust cash reserves.145020Q1 2026
- KRW 305.98bn YTD revenue, lower profit, strong global growth, and robust Derma Cosmetics.145020Q3 2025
- Double-digit sales growth led by botulinum toxin, derma cosmetics, and surging exports.145020Q2 2025
- Q1 2025 saw double-digit profit growth and global expansion, led by Asia Pacific sales.145020Q1 2025
Next Hugel earnings date
Q4 202612 Feb, 2027
Hugel
Next Hugel earnings date
Q4 202612 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Hugel Inc is a South Korea-based biopharmaceutical company specializing in aesthetic and therapeutic medical products. The company develops, manufactures, and markets botulinum toxin products, dermal fillers, and other medical devices used in cosmetic procedures and treatments. Hugel also provides related services for aesthetic clinics and healthcare providers. Its operations include research and development, regulatory compliance, and international distribution, serving both domestic and overseas markets. The company is headquartered in Gangwon-do, South Korea, and its shares are listed on the KRX.